Brief: Omega Therapeutics Announces Clinical Supply Agreement To Evaluate The Combination Of OTX-2002 And Atezolizumab In Hepatocellular Carcinoma
30/03/2023 12:33
March 30 (Reuters) - Omega Therapeutics Inc OMGA.O :
* OMEGA THERAPEUTICS ANNOUNCES CLINICAL SUPPLY AGREEMENT TO
EVALUATE THE COMBINATION OF OTX-2002 AND ATEZOLIZUMAB IN
HEPATOCELLULAR CARCINOMA
* OMEGA THERAPEUTICS INC - ANNOUNCED CLINICAL SUPPLY DEAL
WITH
ROCHE TO EVALUATE OTX-2002 IN COMBINATION WITH ROCHE'S
ANTI-PD-L1 THERAPY
* OMEGA THERAPEUTICS INC - EVALUATION TO BE DONE AS PART OF
CO'S
PHASE 1/2 MYCHELANGELO I CLINICAL TRIAL
* OMEGA THERAPEUTICS INC - UNDER TERMS OF DEAL, ROCHE WILL
SUPPLY
ATEZOLIZUMAB, CO TO EVALUATE COMBINATION AS PART OF OVERALL
CONDUCT OF TRIAL
Source text for Eikon: ID:nGNX4rTscJ
Further company coverage: OMGA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Omega Liquidating
See all newsBrief: Omega Therapeutics Files For Chapter 11 Bankruptcy In U.S. - Court Filing
Brief: Omega Therapeutics Announces Entry Into New Financing Facilities To Fund Sale Process And Wind Down Of Any Remaining Co Assets
Brief: Omega Therapeutics Receives Notice Of Default Under The Loan And Security Agreement Between Company And Banc Of California
U.S. RESEARCH ROUNDUP- Applied Materials, Disney, Walmart
Brief: Flagship Pioneering Announces Appointment Of Junaid Bajwa As Senior Partner, Head Of United Kingdom, And Science Partner For Pioneering Intelligence